

Fycompa Approval Status Worldwide (Country/ Region)

November, 2018

Partial-onset seizures

Australia	May-2014	India	Feb-2016	Philippines	Mar-2015
Austria	Jul-2012	Ireland	Jul-2012	Poland	Jul-2012
Bahrain	Nov-2017	Israel	Aug-2013	Portugal	Jul-2012
Belgium	Jul-2012	Italy	Jul-2012	Romania	Jul-2012
Brazil	May-2016	Japan	Mar-2016	Russia	Aug-2013
Bulgaria	Jul-2012	Jordan	Jul-2016	Saudi Arabia	Jul-2017
Cambodia	Aug-2017	Kuwait	Apr-2015	Singapore	Sep-2014
Canada	Apr-2013	Latvia	Jul-2012	Slovakia	Jul-2012
Croatia	Jun-2014	Lebanon	Dec-2015	Slovenia	Jul-2012
Cyprus	Jul-2012	Liechtenstein	Jul-2012	South Africa	Feb-2016
Czech Republic	Jul-2012	Lithuania	Jul-2012	South Korea	Jul-2015
Denmark	Jul-2012	Luxembourg	Jul-2012	Spain	Jul-2012
Estonia	Jul-2012	Macau	Nov-2014	Sweden	Jul-2012
Finland	Jul-2012	Malaysia	Mar-2014	Switzerland	Dec-2012
France	Jul-2012	Malta	Jul-2012	Taiwan	Aug-2014
Germany	Jul-2012	Mexico	Nov-2014	Thailand	Dec-2014
Greece	Jul-2012	Myanmar	Jul-2016	UAE	Dec-2013
Hong Kong	Apr-2014	Netherlands	Jul-2012	UK	Jul-2012
Hungary	Jul-2012	Norway	Aug-2012	US	Oct-2012
Iceland	Sep-2012	Oman	Jun-2017		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Fycompa Approval Status Worldwide (Country/ Region)

November, 2018

Primary generalized tonic-clonic (PGTC) seizures

Australia	May-2016	Italy	Jun-2015	Singapore	Nov-2016
Austria	Jun-2015	Japan	Mar-2016	Slovakia	Jun-2015
Bahrain	Nov-2017	Jordan	Oct-2018	Slovenia	Jun-2015
Belgium	Jun-2015	Kuwait	Mar-2017	South Korea	Jul-2016
Bulgaria	Jun-2015	Latvia	Jun-2015	Spain	Jun-2015
Canada	Dec-2015	Lebanon	Jul-2016	Switzerland	Mar-2016
Croatia	Jun-2015	Liechtenstein	Jun-2015	Sweden	Jun-2015
Cyprus	Jun-2015	Lithuania	Jun-2015	Taiwan	May-2016
Czech Republic	Jun-2015	Luxembourg	Jun-2015	Thailand	Sep-2017
Denmark	Jun-2015	Macau	Nov-2016	UAE	Dec-2013
Estonia	Jun-2015	Malaysia	Mar-2017	UK	Jun-2015
Finland	Jun-2015	Malta	Jun-2015	US	Jun-2015
France	Jun-2015	Netherlands	Jun-2015		
Germany	Jun-2015	Norway	Jun-2015		
Greece	Jun-2015	Oman	Jun-2017		
Hong Kong	Apr-2016	Philippines	Nov-2015		
Hungary	Jun-2015	Poland	Jun-2015		
Iceland	Jun-2015	Portugal	Jun-2015		
Ireland	Jun-2015	Romania	Jun-2015		
Israel	Nov-2015	Russia	Jun-2015		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.